Last updated: January 9, 2025
Sponsor: Alexandria University
Overall Status: Active - Recruiting
Phase
3
Condition
N/ATreatment
Pethidine Hydrochloride 50 Mg/mL Solution for Injection
Pethidine Hydrochloride 50 Mg/mL Solution for Injection administered intrathecally
Clinical Study ID
NCT06775431
0306931
Ages 20-40 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Exclusion
- Exclusion Criteria:
contraindications to spinal
uncontrolled hypertension, diabetes mellitus, hepatic, pulmonary diseases, andthyroid disease
obesity (BMI >35)
drug allergy
temperature below 36 degrees celcius or above 37.5 degrees celcius
Study Design
Total Participants: 86
Treatment Group(s): 2
Primary Treatment: Pethidine Hydrochloride 50 Mg/mL Solution for Injection
Phase: 3
Study Start date:
December 10, 2024
Estimated Completion Date:
March 31, 2025
Study Description
Connect with a study center
El-Shatby University Hospital
Alexandria,
EgyptActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.